ALIVUSAlivus Life Sciences Ltd.
Alivus Life Sciences acquires 65.01% of IQGEN-X Pharma, which becomes a subsidiary
- Mergers & acquisitions
- pharmaceuticals
Alivus Life Sciences (NSE: ALIVUS) has acquired 7,36,096 equity shares, or 65.01%, of IQGEN-X Pharma Private Limited under a share purchase agreement, making it a subsidiary with effect from 11 Nov 2026, it said in a filing on 11 Nov 2026. The agreement covers a 76% stake.
The acquisition in detail
The company refers to its letter dated 18 Aug 2026 on a share purchase agreement to acquire a 76% stake in IQGEN-X Pharma Private Limited. The closing under that agreement has been initiated, and the company has acquired 7,36,096 equity shares representing 65.01% of IQGEN-X's issued and paid-up equity share capital.
The company says the remaining share capital of IQGEN-X will be acquired in due course. IQGEN-X has become a subsidiary of the company with effect from 11 Nov 2026.
How the step fits the company
Alivus Life Sciences has a market value of about ₹17,862 crore at the 11 Nov 2026 close of ₹1,454.90 a share. Its standalone net profit for the quarter to 30 Sep 2026 was ₹196.75 crore, up 51.3% year on year, as reported in its results filing of 29 Oct 2026.
What the IQGEN-X stake means for Alivus Life Sciences' shareholders
The company now holds a majority of IQGEN-X's equity shares, and the remaining share capital is to follow. The filing does not state the consideration paid, the amount of the deal in rupees, the business IQGEN-X carries on, or the reason and timing for acquiring the rest of the shares. The next step is the acquisition of the remaining share capital, with no date given.
At a glance
| Item | Detail |
|---|---|
| Subsidiary | IQGEN-X Pharma Private Limited |
| Stake targeted | 76% |
| Shares acquired | 7,36,096 equity shares (65.01%) |
| Subsidiary with effect from | 11 Nov 2026 |
| Agreement letter | 18 Aug 2026 |
Filed with BSE on . Reference: Original filing (PDF)
Disclaimer:
The information available on this article is provided for education and informational purposes only. It does not constitute or provide financial, investment or trading advice and should not be construed as an endorsement of any specific stock or financial strategy in any form or manner. We do not make any representations or warranties regarding the quality, reliability, or accuracy of the information provided. This website may contain links to third-party content. We are not responsible for the content or accuracy of these external sources and do not endorse or verify the information provided by third parties. We are not liable for any decisions made or actions taken based on the information provided on this website.